Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value
Jaguar Health, Inc. ( NASDAQ:JAGX ) ('Jaguar' or 'the Company'), announced today that its Board of Directors has unanimously authorized the Company to include cryptocurrency as a treasury reserve asset.
'Cryptocurrencies continue to gain investor attention and acceptance as a major asset class. We believe selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, diversifying our assets to include a digital store of value that we believe has significant upside potential and may also provide a safeguard against inflation,' said Lisa Conte, Jaguar's Founder and CEO. 'Jaguar has been approached by several banks and an investor with terms for cryptocurrency transactions. The Company is assessing the potential value to shareholders, and the potential benefits for our core development programs, of making selected cryptocurrencies a treasury reserve asset for the Company.'
Jaguar's has three core development programs for crofelemer, the Company's novel plant-based prescription medicine: its orphan disease intestinal failure program; its ongoing efforts to make crofelemer available for treatment of cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies; and its ongoing development program to expand access for Canalevia® (crofelemer delayed-release tablets) in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea. Each of these core programs for crofelemer is the subject of business development goals of forging corporate partnerships to bring in non-dilutive funding for the Company.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Canalevia-CA1, visit canalevia.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute 'forward-looking statements.' These include statements regarding making selected cryptocurrencies a treasury reserve asset for the Company, Jaguar's belief that selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, Jaguar's belief that there may be significant upside potential in diversifying the Company's assets to include a digital store of value, Jaguar's belief that diversifying the Company's assets to include a digital store of value may provide a safeguard against inflation, the potential value to shareholders of making selected cryptocurrencies a treasury reserve asset for the Company, and the potential benefits for Jaguar's core development programs of making selected cryptocurrencies a treasury reserve asset for the Company.In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Wolfe Research Upgrades Charter Communications (CHTR) on Potential Tax Benefit
Charter Communications, Inc. (NASDAQ:CHTR) is one of the 11 best performing Warren Buffett stocks in 2025. On June 20, Wolfe Research raised the company's stock from an 'Underperform' rating to a 'Peer Perform' rating. According to the analysts, the key reason for the upgrade is the potential financial benefits for Charter from the anticipated reinstatement of 100% bonus depreciation. A broadband satellite hovering in the sky, highlighting the company's satellite-based broadband communication solutions. In 2017, the Tax Cuts and Jobs Act introduced 100% bonus depreciation. This move allowed companies to deduct the full cost of certain capital expenditures immediately. But this provision began phasing out in 2023. In 2025, the House passed the 'One Big Beautiful Bill', aiming to reinstate full bonus depreciation through 2029 (2030 for some assets). The bill seeks to stimulate capital investment and reduce near-term tax burdens for infrastructure-heavy firms like Charter. Charter stands out as a prime beneficiary with its $93.6 billion debt load and capital-intensive broadband infrastructure. Wolfe Research's analysts highlighted that the company could see $1.8 billion in tax savings in 2025 alone. This is a 30% free cash flow (FCF) boost, potentially doubling FCF per share by 2027. Charter Communications, Inc. (NASDAQ:CHTR) is a broadband connectivity and cable operator company. It provides internet, video, voice, and mobile services to over 32 million customers across 41 US states. Its leading brand is Spectrum, which offers high-speed internet, cable TV, home phone, and mobile services to both residential and business clients. While we acknowledge the potential of CHTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
16 minutes ago
- Miami Herald
The Connection Between Alcohol Use and Psychiatric Conditions
Earn Continuing Education credits and learn about the complex interplay between alcohol use disorder (AUD) and common co-occurring psychiatric conditions, including bipolar disorder, major depressive disorder, and generalized anxiety disorder. ROCKVILLE, MD / ACCESS Newswire / June 26, 2025 / "Providers Clinical Support System - Medications for Alcohol Use Disorder" (PCSS-MAUD) offers new, free training on alcohol use disorder (AUD) and and common co-occurring psychiatric conditions, including bipolar disorder, major depressive disorder, and generalized anxiety disorder. Learners will gain an understanding of how these conditions interact, diagnostic tools and strategies for screening and diagnosis, and evidence-based treatment approaches. An on-demand, interactive module, featuring two national experts, combines theoretical knowledge with practical approaches, ensuring learners are equipped to address these co-occurring conditions in their clinical practice. This online module allows learners to earn 2 continuing education credits upon completion. Alcohol is one of the most used substances in the United States. According to the National Survey on Drug Use and Health, 28.9 million people 12 and older had alcohol use disorder (AUD) in 2023. Many individuals with AUD also have a co-occurring psychiatric condition such as major depressive disorder, anxiety, or bipolar disorder. Estimates suggest that the prevalence of AUD among persons with anxiety disorders and/or mood disorders range from 20-40%. Effectively treating both conditions is essential to supporting recovery. PCSS-MAUD is a national program that provides free training, guidance, and mentoring on the prevention, diagnosis, and treatment of AUD. The program aims to enhance the capacity of physicians, nurse practitioners, physician associates/physician assistants, nurses, pharmacists, substance use disorder counseling professionals, and other health care providers to treat individuals with AUD, including the use of Food and Drug Administration (FDA)-approved MAUD. Learn more and register for this training HERE. Contact Information Amanda Rogalski Marketing Directoraarogalski@ Stephanie Swanson, MPH Director, Federal Programssswanson@ SOURCE: PCSS-MAUD press release
Yahoo
20 minutes ago
- Yahoo
China's $1 Trillion Power Player Is Quietly Backing Out of Wall Street
China Investment Corporationthe $1.3 trillion heavyweight once courted by every major Wall Street firmis stepping back from the U.S. private asset scene. CIC recently pulled the plug on a proposed $1 billion sale of stakes in funds managed by KKR (NYSE:KKR), Carlyle (NASDAQ:CG), and TPG (NASDAQ:TPG), amid concerns it would amplify the optics of its broader U.S. retreat. Insiders say the fund was spooked by the political climate and the potential fallout from being perceived as bailing out of American private equity. While CIC attributes the decision to prudent risk management, the context suggests a deeper recalibration in response to mounting headwinds from both Washington and Beijing. Warning! GuruFocus has detected 4 Warning Signs with CG. This isn't just about one canceled sale. CIConce the savior of Morgan Stanley (NYSE:MS) during the 2008 crisis and an early backer of Blackstonehas been gradually throttling down its U.S. exposure for years. Alternative asset allocations fell below target in 2023. Compliance scrutiny has tightened. And CIC, once central to Wall Street's capital flows, now finds itself sidelined in co-investments and forced into sidecar vehicles to avoid regulatory tangles. New U.S. investment policies under Trump's America First agenda, along with plans to fast-track only friendly foreign investors, are making it harder for Chinese money to find a seat at the table. So where does CIC go next? The fund is doubling down on emerging markets, renewable energy, and dealmaking with Middle Eastern partners. It's still deploying capitalbut with less swagger than before. Internally, capital injections have slowed, talent has trickled out, and its global mandate has been diluted by rising domestic players like Central Huijin. For a fund born to project China's financial influence abroad, CIC is increasingly boxed incaught between politics, regulation, and a shrinking pool of strategic, high-return opportunities. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
